Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular CausesSteven E. Nissen, Kathy Wolski|New England Journal of Medicine|2007Cited by 4.7k
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for ArthritisSteven E. Nissen, A. Michael Lincoff|New England Journal of Medicine|2016Cited by 846
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical TrialsKaren A. Hicks, Robert J. Temple, Eldrin F. Lewis et al.|Circulation|2018Cited by 712
2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical TrialsKaren A. Hicks, Shari Targum, James E. Tcheng et al.|Circulation|2014Cited by 702
2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical TrialsKaren A. Hicks, Shari Targum, James E. Tcheng et al.|Journal of the American College of Cardiology|2014Cited by 596